Abstract
Type 2 diabetes mellitus (T2DM) patients are often accompanied with hypertension. However, the association of antihypertensive drugs with beta-cell function has not been well studied. To investigate this question, the authors performed a cross-sectional study involving 882 hypertensive T2DM patients. To assess beta-cell function, patients were given 75g glucose orally and C-peptide levels before and 1, 2, and 3 hours after glucose intake were measured. Homa-beta was computed by Homeostasis Model Assessment model to evaluate beta-cell function using fasting C-peptide and glucose levels in the plasma. Multivariable-adjusted analysis was performed to evaluate the association of antihypertensive drugs with C-peptide levels, HbA1c, and Homa-beta. Among 882 hypertensive patients, 547 (62.0%) received antihypertensive treatment. Multivariate-adjusted analysis demonstrated that use of calcium channel blockers (CCBs) was negatively associated with HbA1c levels (CCBs: 0.95 [95% CI: 0.92-0.98], P = 0.002). Our data further illustrated that the C-peptide levels before and 1, 2, and 3 hours of OGTT were 1.10-, 1.18-, 1.19-, and 1.15-fold increase in T2DM patients taking CCBs (P = 0.084 for fasting C-peptide levels; P = 0.11). In conclusion, CCB treatment was negatively associated with HbA1c levels but positively associated with beta-cell function in hypertensive T2DM patients, implying that CCBs could be considered to treat hypertensive T2DM patients with reduced beta-cell function.
Original language | English |
---|---|
Pages (from-to) | 638-647 |
Number of pages | 10 |
Journal | Journal of Clinical Hypertension |
Volume | 21 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2019 |
Keywords
- calcium channel blocker
- hypertension
- inhibitor of renin-angiotensin-aldosterone system
- type 2 diabetes mellitus
- beta-cell function
- HYPERTENSIVE PATIENTS
- RECEPTOR BLOCKADE
- ANGIOTENSIN-II
- ER STRESS
- RENIN
- ALDOSTERONE
- INHIBITION
- PREVALENCE
- PROTECTION
- SYSTEM